KRAS and neoplasm: Oncogenic KRAS mutations actively participate in multiple metabolic processes, including lipometabolism, glycometabolism, amino acid metabolism, and nucleotide metabolism, to meet the high biosynthetic demands and accelerate tumor cell proliferation.